Analytical Data
-
Gene name
EYA2
- Application
-
Alternative Names
EYA2；EAB1;Eyes absent homolog 2
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00167
-
Expression Region
244-514aa
-
AA Sequence
MGSSHHHHHH SSGLVPRGSH MGSMERVFVW DLDETIIIFH SLLTGTFASR YGKDTTTSVR IGLMMEEMIF NLADTHLFFN DLEDCDQIHV DDVSSDDNGQ DLSTYNFSAD GFHSSAPAAN LCLGSGVHGG VDWMRKLAFR YRRVKEMYNT YKNNVGGLIG TPKRETWLQL RAELEALTDL WLTHSLKALN LINSRPNCVN VLVTTTQLIP ALAKVLLYGL GSVFPIENIY SATKTGKESC FERIMQRFGR KAVYVVIGDG VEEEQGAKKH NMPFWRISCH ADLEALRHAL ELEYL
-
Molecular Weight
33 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EYA2 is a member of the EYA family of proteins, which play crucial roles in various biological processes, including development, organogenesis, and cellular signaling. Initially identified for its involvement in the development of the eye and other organs, EYA2 functions as a transcriptional co-activator that interacts with other proteins to regulate gene expression. Research has shown that EYA2 is not only essential during embryonic development but also implicated in several diseases, including cancers. Its expression levels have been correlated with tumor progression and poor prognosis in various malignancies. The recombinant EYA2 protein has become a focus of research to better understand its functional properties, interactions, and role in pathophysiological conditions. The production of EYA2 as a recombinant protein allows for detailed biochemical and biophysical studies, facilitating the investigation of its structure-function relationships. Additionally, characterizing EYA2's interactions with other cellular components can provide insights into its regulatory mechanisms and potential implications for therapeutic interventions. Given its significant role in both development and disease, ongoing research on EYA2 is vital for uncovering its full spectrum of functions and developing targeted strategies to modulate its activity in clinical settings.
